First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
- Registration Number
- NCT04767594
- Lead Sponsor
- Pfizer
- Brief Summary
This is a prospective, single-arm, multi-center observational non-interventional study (NIS) in Germany and Austria.
- Detailed Description
Patients diagnosed with HR+/HER2- locally advanced or metastatic breast cancer indicated by their treating physicians for first line endocrine-based palbociclib combination therapy and who meet eligibility criteria will be invited to participate in this study. The key objectives of this study are to describe clinical, scientific and patient reported outcomes for patients with HR+/HER2- locally advanced or metastatic breast cancer initiating treatment with first line endocrine-based palbociclib combination therapy in the real-world setting in Germany and Austria. Patient characteristics, real-world treatment patterns, treatment sequences and reasons for the physician's treatment decisions will be collected. Additional real-world research questions are to explore patient-focused parameters such as longitudinal follow-up data on patient-reported outcomes beyond disease progression and by treatment sequence or to analyze the time from the start of first line treatment to the first administered palliative chemotherapy. Clinical outcome by treatment sequences will be described. Routinely assessed biomarkers and diagnostic procedures applied for treatment sequence decisions will be collected.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1900
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description First-line Palbociclib + endocrine therapy Palbociclib + endocrine therapy Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) from date of start of first-line treatment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 7.5 years
- Secondary Outcome Measures
Name Time Method Time to first subsequent therapy (TFST) from date of start of first-line treatment until the date of start of first subsequent systemic antineoplastic treatment, assessed up to 7.5 years Landmark progression-free survival rates (PFSR) of first- and second-line treatment proportion of patients without documented disease progression or death due to any cause at defined intervals after start of first-/second-line treatment (at 6, 12, 18, 24, 30, 36 months) Duration of response (DoR) of first- and second-line treatment from the date of first documented tumor response during first-/ second-line treatment until to the date of first subsequent documented disease progression or to death due to any cause, whichever came first, assessed up to 7.5 years Landmark overall survival rates (OSR) proportion of patients without documented death due to any cause at defined intervals (at 12, 24, 36, 48, 60 months after start of first-line treatment) Objective response rate (ORR) of first- and second-line treatment from date of start of first-/ second-line treatment until the date of first subsequent documented disease progression or date of death from any cause, whichever came first, assessed up to 7.5 years Change from baseline in the FACT-B subscales scores: PWB, SWB, EWB, FWB and additional concerns for BCS. from the date of first questionnaire assessment until the date of last questionnaire assessment, assessed at baseline, thereafter 3-monthly until end of study, and at the end of palbociclib treatment, up to 7.5 years. The FACT-B is a 37-item instrument designed to measure five domains of HRQOL in breast cancer patients: PWB, SWB, EWB, FWB as well as a BCS. Utilized with the 27 core FACT-G items, the FACT-B was developed with an emphasis on patients' values and brevity.
For all questions, participants are asked to respond to a 5-point Likert-type scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The higher the score, the better the QOL (PWB: minimum 0; maximum 28. SWB: minimum 0; maximum 28. EWB: minimum 0; maximum 24. FWB: minimum 0; maximum 28. BCS: minimum 0; maximum 40).Cohort-specific PFS of second-line treatment from date of start of second-line treatment until the date of first subsequent documented disease progression or date of death from any cause, whichever came first, assessed up to 7.5 years Cohorts are defined by substance class of second-line therapy following first-line endocrine-based palbociclib therapy
Cohort-specific PFS2 from date of start of first-line treatment until the date of documented disease progression on the respective second-line treatment or date of death from any cause, whichever came first, assessed up to 7.5 years Disease control rate (DCR) of first- and second-line treatment proportion of patients with documented tumor response during first-/second-line treatment (as assessed by local investigator in routine clinical practice) or stable disease (SD) over a period of at least 24 weeks after start of first-line treatment Progression-free survival (PFS) of third-line treatment from date of start of third-line treatment until the date of first subsequent documented disease progression or date of death from any cause, whichever came first, assessed up to 7.5 years Change from baseline in the FACT-G total score from the date of first questionnaire assessment until the date of last questionnaire assessment, assessed at baseline, thereafter 3-monthly until end of study, and at the end of palbociclib treatment, up to 7.5 years. The FACT-G is a 27-item instrument designed to measure four domains of HRQOL in breast cancer patients: PWB, SWB, EWB, and FWB.
For all questions, participants are asked to respond to a 5-point Likert-type scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The higher the score, the better the QOL (minimum 0; maximum 108).Landmark analyses of cohort-specific Area Under the Curve (AUC) in the Functional Assessment of Cancer Therapy - Breast (FACT-B) TOI-Physical/Functional/Breast (TOI-PFB) From the date of first questionnaire assessment until 12, 24, 36, 48 months thereafter (irrespective of disease or treatment situation at that time point) Cohorts are defined by substance class of second-line therapy following first-line endocrine-based palbociclib therapy.
Overall survival (OS) from date of start of first-line treatment until the date of documented death from any cause, assessed up to 7.5 years Change from baseline in the FACT-B total score from the date of first questionnaire assessment until the date of last questionnaire assessment, assessed at baseline, thereafter 3-monthly until end of study, and at the end of palbociclib treatment, up to 7.5 years. The FACT-B is a 37-item instrument designed to measure five domains of Health-Relaed Quality of Life (HRQOL) in breast cancer patients: Physical Well-being (PWB), Social/family Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) as well as a Breast Cancer Subscale (BCS).
Utilized with the 27 core FACT-G items, the FACT-B was developed with an emphasis on patients' values and brevity.
For all questions, participants are asked to respond to a 5-point Likert-type scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The higher the score, the better the QOL (minimum 0; maximum 148).Time to first subsequent chemotherapy (TFSC) from date of start of first-line treatment until the date of start of first subsequent systemic chemotherapy or chemotherapy-based antineoplastic treatment, assessed up to 7.5 years Change from baseline in FACT-B Trial Outcome Index (TOI) from the date of first questionnaire assessment until the date of last questionnaire assessment, assessed at baseline, thereafter 3-monthly until end of study, and at the end of palbociclib treatment, up to 7.5 years. The FACT-B is a 37-item instrument designed to measure five domains of HRQOL in breast cancer patients: PWB, SWB, EWB, FWB as well as a BCS. Utilized with the 27 core FACT-G items, the FACT-B was developed with an emphasis on patients' values and brevity. The TOI combines the PWB+FWB+BCS items, making it 24-items altogether.
For all questions, participants are asked to respond to a 5-point Likert-type scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The higher the score, the better the QOL (minimum 0; maximum 96).Time to deterioration (TTD) in FACT-B total score From the date of first questionnaire assessment until the date of first subsequent questionnaire with a decrease of ≥ 7 points in FACT-B total score or death, whichever came first, assessed up to 7.5 years. The FACT-B is a 37-item instrument designed to measure five domains of HRQOL in breast cancer patients: PWB, SWB, EWB, FWB as well as a BCS. Utilized with the 27 core FACT-G items, the FACT-B was developed with an emphasis on patients' values and brevity.
For all questions, participants are asked to respond to a 5-point Likert-type scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The higher the score, the better the QOL (minimum 0; maximum 148).
Trial Locations
- Locations (205)
Hämatologisch Onkologisches Studieninstitut
🇩🇪Mayen, Germany
Sankt Josef Hospital Braunau
🇦🇹Braunau, Austria
Medizinische Universität Innsbruck
🇦🇹Innsbruck, Austria
Klinikum Klagenfurt am Woerthersee
🇦🇹Klagenfurt Am Woerthersee, Austria
Country Hospital Salzburg
🇦🇹Salzburg, Austria
Universitaetsklinikum Sankt Poelten
🇦🇹Sankt Poelten, Austria
Priv. Doz. OA Dr. Michael Hubalek
🇦🇹Schwaz, Austria
Oesterreichische Gesundheitskasse Hanusch-Krankenhaus
🇦🇹Vienna, Austria
Medizinische Universität Wien, Abteilung Innere Medizin I
🇦🇹Wien, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
Klinikum Nürnberg
🇩🇪Nuernberg, Bavaria, Germany
Klinikum Bayreuth GmbH
🇩🇪Bayreuth, Bayern, Germany
Onkologische Kooperation Harz
🇩🇪Goslar, Niedersachsen, Germany
Caritas-Krankenhaus Bad Mergentheim
🇩🇪Bad Mergentheim, Other, Germany
Mvz Etgo Gmbh
🇩🇪Berlin, Other, Germany
Onkologisch-Hämatologische Schwerpunktpraxis
🇩🇪Bremen, Other, Germany
ANregiomed gKU
🇩🇪Ansbach, Germany
Klinikum Hochsauerland GmbH
🇩🇪Arnsberg, Germany
Group practice Heinrich
🇩🇪Augsburg, Germany
Group Practice Steinfeld-Birg
🇩🇪Augsburg, Germany
Group practice Tanzer
🇩🇪Bad Reichenhall, Germany
Group practice Seipelt
🇩🇪Bad Soden a.T., Germany
Klinikum Mittelbaden Baden-Baden Balg
🇩🇪Baden-Baden, Germany
Sozialstiftung Bamberg Klinikum am Bruderwald
🇩🇪Bamberg, Germany
Private Practice Bayreuth
🇩🇪Bayreuth, Germany
Charité - Universitaetsmedizin Berlin, Charité Campus Mitte
🇩🇪Berlin, Germany
Charité Campus Mitte
🇩🇪Berlin, Germany
Hämatologie Onkologie Berlin-Mitte
🇩🇪Berlin, Germany
Private practice Schilling
🇩🇪Berlin, Germany
MediOnko-Institut GbR
🇩🇪Berlin, Germany
DRK Kliniken Berlin-Köpenick Brustzentrum
🇩🇪Berlin, Germany
Private practice Ruhmland
🇩🇪Berlin, Germany
Group practice Morack
🇩🇪Berlin, Germany
Vivantes Netzwerk für Gesundheit GmbH
🇩🇪Berlin, Germany
Frauenarzt-Zentrum-Zehlendorf
🇩🇪Berlin, Germany
Dr. Leonid Basovski Hämatologikum Biberach
🇩🇪Biberach an der Riss, Germany
Evangelisches Klinikum Bethel gGmbH, Klinik für Innere Medizin, Hämatologie, Onkologie
🇩🇪Bielefeld, Germany
Group practice Bueckner
🇩🇪Bochum, Germany
Kliniken Boeblingen
🇩🇪Boeblingen, Germany
Praxiskooperation Onkologie Bonn / Euskirchen / Rheinbach / Wesseling GbR
🇩🇪Bonn, Germany
Group practice Hannig
🇩🇪Bottrop, Germany
Marienhospital Bottrop gGmbH
🇩🇪Bottrop, Germany
ONKO DOK GbR
🇩🇪Bottrop, Germany
Private practice Brandenburg a.d.H.
🇩🇪Brandenburg a.d.H., Germany
Staedtisches Klinikum Brandenburg GmbH
🇩🇪Brandenburg an der Havel, Germany
Klinikum Bremerhaven Reinkenheide gGmbH
🇩🇪Bremerhaven, Germany
Fürst-Stirum-Klinik Bruchsal Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Bruchsal, Germany
Group practice Schieder
🇩🇪Buchholz, Germany
AKH-Gruppe-Allgemeines Krankenhaus Celle + MVZ gGmbH
🇩🇪Celle, Germany
Klinikum Chemnitz gGmbH
🇩🇪Chemnitz, Germany
Private Practice Jungberg
🇩🇪Chemnitz, Germany
St. Vincenz-Krankenhaus
🇩🇪Datteln, Germany
DONAUISAR Klinikum
🇩🇪Deggendorf, Germany
Onkologiezentrum Donauwoerth
🇩🇪Donauwoerth, Germany
Klinikum Dortmund Frauenklinik
🇩🇪Dortmund, Germany
Studiengesellschaft Gefos Dortmund mbH
🇩🇪Dortmund, Germany
Group practice Goehler
🇩🇪Dresden, Germany
Gemeinschaftspraxis
🇩🇪Dresden, Germany
Group practice Jacobasch
🇩🇪Dresden, Germany
St. Marien-Hospital
🇩🇪Dueren, Germany
MVZ Duisburg Süd GmbH
🇩🇪Duisburg, Germany
Naedler GmbH
🇩🇪Duisburg, Germany
Private Practice Groell
🇩🇪Ebersberg, Germany
Studienzentrale für das MVZ Eggenfelde e.K.
🇩🇪Eggenfelden, Germany
St. Georg Klinikum Eisenach gGmbH
🇩🇪Eisenach, Germany
Group practice Weniger
🇩🇪Erfurt, Germany
Group practice Haecker
🇩🇪Erlangen, Germany
imland gGmbH
🇩🇪Fockbek, Germany
Universitaetsklinikum Frankfurt Frauenheilkunde
🇩🇪Frankfurt am Main, Germany
pioh Studien und Management GbR
🇩🇪Frechen, Germany
Group Practice Dr. med. M. Zaiss
🇩🇪Freiburg, Germany
private practice Freital
🇩🇪Freital, Germany
KKH Landkreis Freudenstadt Frauenheilkunde und Geburtshilfe
🇩🇪Freudenstadt, Germany
Krankenhaeuser Landkreis Freudenstadt
🇩🇪Freudenstadt, Germany
Group practice Fuerth
🇩🇪Fuerth, Germany
MVZ II der Niels Stensen Kliniken
🇩🇪Georgsmarienhuette, Germany
Onkostudien Gera GbR
🇩🇪Gera, Germany
Private practice Rabenbauer
🇩🇪Grafenau, Germany
Private Practice Antje Kristina Belau
🇩🇪Greifswald, Germany
Onkodok GmbH
🇩🇪Guetersloh, Germany
Klinikum Oberberg KKH Gummersbach
🇩🇪Gummersbach, Germany
Group practice Neumeister
🇩🇪Haldensleben, Germany
Group practice Behlendorf
🇩🇪Halle (Saale), Germany
Studiengesellschaft Haemato-Onkologie Hamburg GbR
🇩🇪Hamburg, Germany
Praxisklinik Harburger Ring
🇩🇪Hamburg, Germany
Katholisches Marienkrankenhaus gGmbH Frauenklinik
🇩🇪Hamburg, Germany
Überörtliche Gemeinschaftspraxis
🇩🇪Hamburg, Germany
Private Practice Rubanov
🇩🇪Hameln, Germany
Klinikum Hanau Gynäkologisches Krebszentrum
🇩🇪Hanau, Germany
Group Practice Kamal
🇩🇪Hannover, Germany
Private Practice Fuxius
🇩🇪Heidelberg, Germany
Private practice Petersen
🇩🇪Heidenheim a.d.B., Germany
Westkuestenkliniken Heide und Brunsbuettel
🇩🇪Heide, Germany
Gemeinschaftskrankenhaus Herdecke gGmbH
🇩🇪Herdecke, Germany
Mathilden-Hospital
🇩🇪Herford, Germany
cancer Center Zweiseenland GbR
🇩🇪Herrsching, Germany
Private Practice Dr. med. Andreas Lorenz
🇩🇪Hildburghausen, Germany
Gemeinschaftspraxis Dr.med. Ch. Uleer
🇩🇪Hildesheim, Germany
Onkologie Hof MVZ GmbH
🇩🇪Hof, Germany
Universitätsklinik des Saarlandes Ausführende Stelle: Universitätsklinikum Homburg,
🇩🇪Homberg, Germany
Frauenarzt Toralf Baerens
🇩🇪Ilsede, Germany
Klinikum Itzehoe
🇩🇪Itzehoe, Germany
IDGGQ GbR
🇩🇪Kaiserslautern, Germany
ViDia Christliche Kliniken Karlsruhe Vincentius-Diakonissen-Kliniken gAG
🇩🇪Karlsruhe, Germany
Diakonissenkrankenhaus Karlsruhe
🇩🇪Karlsruhe, Germany
Klinikum Kaufbeuren
🇩🇪Kaufbeuren, Germany
Institut fuer Versorgungsforschung in der Onkologie GbR
🇩🇪Koblenz, Germany
private practice Ziegler-Loehr
🇩🇪Koeln, Germany
St. Elisabeth Krankenhaus GmbH
🇩🇪Koeln, Germany
Group practice Koeln
🇩🇪Koeln, Germany
group practice Krefeld
🇩🇪Krefeld, Germany
Private practice Kronach
🇩🇪Kronach, Germany
Klinikum Kulmbach
🇩🇪Kulmbach, Germany
Klinikum Dahme-Spreewald GmbH
🇩🇪Königs Wusterhausen, Germany
ÜBAG - MVZ Dr. Vehling-Kaiser GmbH Landshut
🇩🇪Landshut, Germany
Group practice Koehler
🇩🇪Langen, Germany
Onkologisches Zentrum Lebach
🇩🇪Lebach, Germany
Group practice Mueller
🇩🇪Leer, Germany
Group practice Knoblich
🇩🇪Loerrach, Germany
Private practice Wierick
🇩🇪Lohsa, Germany
Universitätsklinikum Schleswig Holstein
🇩🇪Luebeck, Germany
Onkologie Zentrum Lüneburg Praxisgemeinschaft
🇩🇪Lüneburg, Germany
Universitätsklinikum Magdeburg Frauenklinik, Brustzentrum
🇩🇪Magdeburg, Germany
Klinikum Magdeburg Frauenheilkunde und Geburtshilfe
🇩🇪Magdeburg, Germany
Group practice Prof. Dr. M. Hensel
🇩🇪Mannheim, Germany
Klinikum Fichtelgebirge gGmbH
🇩🇪Marktredwitz, Germany
Institut für Versorgungsforschung GbR
🇩🇪Mayen, Germany
Brustzentrum-Rhein-Ruhr Servicegesellschaft mbH
🇩🇪Moenchengladbach, Germany
OnkoLog Moers GbR
🇩🇪Moers, Germany
Onko - Log Muelheim GbR
🇩🇪Muehlheim, Germany
Klinikum Dritter Orden
🇩🇪Muenchen, Germany
Group practice Schmidt
🇩🇪Muenchen, Germany
MVZ GmbH-Muehlhausen
🇩🇪Muhlhausen, Germany
Stauferklinikum Schwaebisch Gmuend
🇩🇪Mutlangen, Germany
Private practice Naunhof
🇩🇪Naunhof, Germany
Frauenärztin Neubrandenburg - Dr. m Ines Vanselow-Geßner
🇩🇪Neubrandenburg, Germany
Group Practice Nacke
🇩🇪Neuenahr-Ahrweller, Germany
Friedrich-Ebert-Krankenhaus
🇩🇪Neumuenster, Germany
Augustinus Kliniken, JEK
🇩🇪Neuss, Germany
TZN-Tumorzentrum Niederrhein GmbH
🇩🇪Neuss, Germany
Group practice Tschechne
🇩🇪Neustadt a.R., Germany
Group practice Hutzschenreuter
🇩🇪Nordhorn, Germany
Spital 2 medizinisches Institut PartG mbB
🇩🇪Nuernberg, Germany
medius Klinik Nürtingen
🇩🇪Nuertingen, Germany
group practice Olbermann
🇩🇪Oberhausen, Germany
ONSO GbR
🇩🇪Oldenburg, Germany
Pius Hospital Oldenburg
🇩🇪Oldenburg, Germany
Oberhavel Kliniken GmbH
🇩🇪Oranienburg, Germany
Klinikum Osnabrueck GmbH
🇩🇪Osnabrueck, Germany
Paracelsus-Klinik Osnabrueck
🇩🇪Osnabrueck, Germany
St. Vincenz-Krankenhaus GmbH
🇩🇪Paderborn, Germany
Klinikum Ernst von Bergmann gGmbH
🇩🇪Potsdam, Germany
MVZ für Blut - und Krebserkrankungen Drs. Sauer / Gerhardt / Linde
🇩🇪Potsdam, Germany
Group practice Decker
🇩🇪Ravensburg, Germany
Oncologianova GmbH
🇩🇪Recklinghausen, Germany
Group practice Remscheid
🇩🇪Remscheid, Germany
Private practice Remscheid
🇩🇪Remscheid, Germany
Private practice Kohnke
🇩🇪Remscheid, Germany
Gemeinschaftspraxis für internistische Hämatologie und Onkologie
🇩🇪Rheine, Germany
Private practice Markmann
🇩🇪Rostock, Germany
Klinikum Suedstadt Rostock, Universitaetsfrauenklinik
🇩🇪Rostock, Germany
Agaplesion Diakonieklinik Rotenburg gGmbH
🇩🇪Rotenburg (Wuemme), Germany
GPR Klinikum Rüsselsheim
🇩🇪Ruesselsheim, Germany
CaritasKlinikum St. Theresia
🇩🇪Saarbrücken, Germany
Krankenhaus Saarlouis vom DRK
🇩🇪Saarlouis, Germany
Private practice Schubert
🇩🇪Scheibenberg, Germany
MedCenter Nordsachsen - Studien
🇩🇪Schkeuditz, Germany
Onkster GbR
🇩🇪Schorndorf, Germany
Diakoneo Diakonie-Klinikum Schwaebisch Hall gGmbH
🇩🇪Schwaebisch Hall, Germany
Leopoldina Krankenhaus der Stadt Schweinfurt GmbH
🇩🇪Schweinfurt, Germany
Marienkrankenhaus Schwerte
🇩🇪Schwerte, Germany
Group Practice Esser
🇩🇪Siegburg, Germany
Group practice Singen
🇩🇪Singen (Hohentwiel), Germany
KMG Klinikum Sömmerda
🇩🇪Soemmerda, Germany
Onkologiezentrum Soest/Iserlohn
🇩🇪Soest, Germany
Staedtisches Klinikum Solingen gemeinützige GmbH, Klinik für Frauenheilkunde
🇩🇪Solingen, Germany
Group practice Behringer
🇩🇪Speyer, Germany
MVZ Klinik Dr. Hancken GmbH
🇩🇪Stade, Germany
Private Practice Denck
🇩🇪Stendal, Germany
Clinical Research Stohlberg GmbH
🇩🇪Stohlberg, Germany
Private practice Stralsund
🇩🇪Stralsund, Germany
Gynäkologie Kompetenzzentrum Praxis Dr. med. Carsten Hielscher
🇩🇪Stralsund, Germany
Klinikum der Landeshauptstadt Stuttgart gKAoeR
🇩🇪Stuttgart, Germany
Vinzenz von Paul Kliniken gGmbH Marienhospital
🇩🇪Stuttgart, Germany
Frauenaerztliches Zentrum Suhl im medico Facharztzentrum MVZ GmbH Betriebsstaette Suhl
🇩🇪Suhl, Germany
SRH Zentralklinikum Suhl GmbH
🇩🇪Suhl, Germany
Group Practice Kronawitter
🇩🇪Traunstein, Germany
Klinikum Traunstein
🇩🇪Traunstein, Germany
Group practice Forstbauer
🇩🇪Troisdorf, Germany
Private practice Weissenborn
🇩🇪Twistringen, Germany
Private practice Wolf
🇩🇪Ulm, Germany
Group practice Wagner
🇩🇪Voelklingen, Germany
GRN Klinik Weinheim
🇩🇪Weinheim, Germany
Asklepios Klinik Weissenfels Frauenheilkunde, Geburtshilfe Brustzentrum
🇩🇪Weissenfels, Germany
MVZ Marien-Hospital Wesel GmbH
🇩🇪Wesel, Germany
Medizinische Studiengesellschaft NORD-WEST GmbH
🇩🇪Westerstede, Germany
Lahn-Dill-Kliniken GmbH
🇩🇪Wetzlar, Germany
Helios Dr. Horst Schmidt Kliniken Wiesbaden
🇩🇪Wiesbaden, Germany
Gruop practice Rodemer / Wismann / Distelrath
🇩🇪Wilhelmshaven, Germany
Rems-Murr-Klinikum Winnenden Gynaekologie und Geburtshilfe
🇩🇪Winnenden, Germany
GIM - Gemeinschaftspraxis Innere Medizin
🇩🇪Witten, Germany
Group practice Wolfsburg
🇩🇪Wolfsburg, Germany
Group practice Wuerzburg
🇩🇪Wuerzburg, Germany
Universitätsklinikum Wuerzburg AoeR
🇩🇪Wuerzburg, Germany
Helios Universitätsklinikum Wuppertal GmbH
🇩🇪Wuppertal, Germany